Researching Safety and Cost-Effectiveness in the Life Cycle of Nanomedicine
Journal of Law & Medicine, Vol. 15, 2007
8 Pages Posted: 22 May 2009
Date Written: May 22, 2007
Abstract
Nanotechnology is rapidly emerging as a transformational influence on many industry sectors. This is particularly true of medicines and medical devices. This article argues that, as policy interest in devising an appropriate regulatory framework for nanotherapeutics escalates, it will be important for public health to ensure that a broad life-cycle approach to both safety and cost-effectiveness is adopted. It charts some of the most important issues likely to be faced and begins to map how they can best be addressed.
Keywords: Nanotechnology, safety, cost-effectiveness, drug regulation, nanomedicine
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
The Challenge of Developing Oversight Approaches to Nanobiotechnology
By Jordan Paradise, Susan M. Wolf, ...
-
The Challenge of Developing Oversight Approaches to Nanobiotechnology
-
Developing Oversight Frameworks for Nanobiotechnology
By Jordan Paradise, Susan M. Wolf, ...
-
Stakeholder Participation in New Governance: Lessons from Chicago's Public Housing Reform Experiment
-
Unpackaging Synthetic Biology: Identification of Policy Problems and Options
By Jennifer Kuzma and Todd Tanji
-
Dynamic Governance: Embedding Culture, Capabilities and Change in Singapore
By Boon Siong Neo and Geraldine Chen
-
Gene Therapy Oversight: Lessons for Nanobiotechnology
By Susan M. Wolf, Rishi Gupta, ...
-
Continued Concern: Human Subject Protection, the Irb, and Continuing Review